Hospice & Palliative Care: Optimal Management for Serious Illness
Dates and Times
Start: 3/25/2020 7:45 AM
End: 3/25/2020 8:45 AM
As a result of attending this activity the learner will be better able to:
1. Describe approaches to target identification in drug development.
2. Summarize the linear process of drug development once a target has been identified.
3. Discuss the prostaglandin F2-alpha in NAFLD-NASH as an example of current drug development.
Lecture Hall 2
101 Nicolls Road
Stony Brook, NY 11794
The School of Medicine, State University of New York at Stony Brook, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The School of Medicine, State University of New York at Stony Brook designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s) ™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.
Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.